Merck’s Dividend Dilemma: Can Growth Sustain Value?

Merck’s (MRK) stock price has surged 36% year-to-date, outpacing the Nasdaq Composite’s 12% gain over the same period. This impressive performance raises questions about whether the company can maintain its growth trajectory while keeping dividend yields intact.

The acquisition of Terns Pharmaceuticals in May for $6.7 billion is a key aspect of Merck’s success story. The deal has given Merck access to promising oral cancer treatment TERN-701, which has garnered a Breakthrough Therapy Designation from the FDA and shown early trial data that is encouraging. However, this strategic maneuver comes with significant costs – $5.7 billion in charges tied to the acquisition and R&D spending have pushed Merck’s GAAP net income into negative territory.

These costs may be temporary, but they raise concerns about Merck’s ability to maintain its growth pace without compromising its financial health. Analysts expect EPS to decline 69% in full-year 2026 compared to the prior year, despite a raised sales forecast for $66.3 billion to $67.3 billion. The forward payout ratio stands at 103.5%, indicating expected dividend payments may outstrip projected earnings.

Merck has consistently demonstrated its commitment to shareholders through its 15-year streak of annual dividend increases and an impressive yield above 2.3%. However, investors would do well to scrutinize the company’s financials more closely in light of these rising costs and one-time charges. As we approach the end of 2026, Merck’s balance sheet will be put to the test.

The pharmaceutical industry is facing intense pressure due to regulatory challenges, patent expirations, and increasing competition from generic players. Amidst this backdrop, Merck’s reliance on its oncology business – driven largely by Keytruda sales – is a significant risk factor that demands attention.

The partnership with Moderna (MRNA) is a promising development for Merck’s cancer pipeline, but it remains to be seen how this collaboration will translate into tangible returns. Meanwhile, the company’s $1 billion deal with Alphabet’s Google Cloud holds potential benefits in areas such as AI-driven research and manufacturing optimization, but its impact on growth and profitability will take time to materialize.

Investors should not expect a risk-free ride from Merck stock in 2027, despite the consensus “Moderate Buy” rating and average price target of $154.96 indicating potential upside. The uncertainty surrounding Merck’s near-term prospects underscores the complexity of its financial narrative. Only time will tell if Merck can sustain its remarkable growth while maintaining value for investors.

As Merck approaches its next quarterly results on October 29, one thing remains certain: its dividend dilemma serves as a stark reminder that even in the best of times, the line between growth and sustainability is thin.